News
Nasus Pharma presented clinical results of intranasal epinephrine in EAACI, July 2022, Prague
July 28, 2022
A Novel Faster‑Acting, Dry Powder‑Based, Naloxone Intranasal Formulation for Opioid Overdose
Nasus Pharma announces publication of its pivotal study comparing its FMXIN001 powder nasal Naloxone to Narcan®
April 12, 2022
A Novel Faster‑Acting, Dry Powder‑Based, Naloxone Intranasal Formulation for Opioid Overdose
More News
